Serial #79286383
LIVE

Serial Number

79286383

Owner

NEUWAY Pharma GmbH

Attorney

Leigh Ann Lindquist

Filing Date

Apr 15, 2020

Add to watchlist:

No watchlists yet
View on USPTO

Serial #79286383 Trademark

Serial Number: 79286383 • Registration: 6331130

Serial #79286383 is a trademark filed by NEUWAY Pharma GmbH on April 15, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

NEUWAY Pharma GmbH (4 trademarks)

Bonn 53117 , DE

Entity Type: 99

Trademark Details

Filing Date

April 15, 2020

Registration Date

April 27, 2021

Published for Opposition

February 9, 2021

Goods & Services

Chemical, biological, biochemical and biotechnological products and preparations for industrial and scientific purposes, namely, small molecules, biologics, nucleic acids, proteins, lipids, polysaccharides, enzymes, antibodies, cells, microorganisms as well as fragments, fractions, derivatives, components and lysates thereof; chemical, biological, biochemical and biotechnological chemical products and preparations for laboratory or research use and manufacturing use, namely, small molecules, biologics, nucleic acids, proteins, lipids, polysaccharides, enzymes, antibodies, cells, microorganisms as well as fragments, fractions, derivatives, components and lysates thereof

Scientific research and development for others, in particular in the fields of medicine, pharmacy, diagnostics, chemistry, biology, biochemistry and biotechnology; scientific research and development as well as biotechnological research and development services for others with regard to manufacturing pharmaceutical preparations, implants comprising active ingredients, carriers for active ingredients and drug delivery systems for medical use in humans or animals; development of pharmaceutical preparations, namely, medical products for the prevention and treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination or immunostimmulation, for others

Chemical, biological, biochemical and biotechnological products and preparations for medical, veterinary and pharmaceutical purposes for the prevention and treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination or immunostimmulation, namely, small molecules, biologics, nucleic acids, proteins, lipids, polysaccharides, enzymes, antibodies, cells, microorganisms as well as fragments, fractions and derivatives thereof; diagnostic preparations for medical and veterinary use; vaccines; healthcare preparations, medicines, medicinal preparations, pharmaceutical preparations and pharmaceutical substances for the prevention and treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination or immunostimmulation; pharmaceutical preparations and substances, namely, adjuvants, carriers for active ingredients and drug delivery systems comprising protein based capsids or particles for the release of therapeutic or diagnostic agents for medical use in humans or animals; biological implants comprising active ingredients

Manufacture of pharmaceutical products, medicinal products, and medicaments from pharmaceutical compositions for others

Filing History

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Apr 27, 2026 REM3
CHANGE OF NAME/ADDRESS REC'D FROM IB
Apr 23, 2022 ADCH
FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 29, 2021 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 5, 2021 FICS
FINAL DISPOSITION PROCESSED
Aug 5, 2021 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 27, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Apr 27, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 9, 2021 NPUB
PUBLISHED FOR OPPOSITION
Feb 9, 2021 PUBO
NOTIFICATION PROCESSED BY IB
Feb 6, 2021 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 20, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 20, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 20, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 4, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 4, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 4, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 4, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 4, 2021 CNEA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 16, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 16, 2020 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Dec 16, 2020 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 16, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 16, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Dec 16, 2020 COAR
REFUSAL PROCESSED BY IB
Sep 5, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 16, 2020 RFCS
REFUSAL PROCESSED BY MPU
Aug 15, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 11, 2020 RFCR
NON-FINAL ACTION WRITTEN
Jul 10, 2020 CNRT
ASSIGNED TO EXAMINER
Jul 6, 2020 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 12, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 8, 2020 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jun 5, 2020 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 28, 2020 REPR